SIGLEC-3 (also known as CD33) is a member of the sialic acid-binding immunoglobulin-type lectin (SIGLEC) family that is expressed on myeloid cells, including microglia in the brain[1]. As a risk gene for Alzheimer's disease (AD), SIGLEC-3 represents a promising therapeutic target for modulating microglial function in neurodegeneration[2]. This page reviews the biology of SIGLEC-3 in microglia, compares it to TREM2, evaluates preclinical evidence for targeting, and discusses emerging therapeutic strategies including bispecific antibodies and delivery approaches.
SIGLEC-3 (CD33) is a type I transmembrane receptor belonging to the SIGLEC family of sialic acid-binding lectins[1:1]. It contains an extracellular V-type immunoglobulin-like domain that recognizes sialic acid residues on glycoproteins and glycolipids, a transmembrane domain, and a cytoplasmic tail with immunoreceptor tyrosine-based inhibitory motifs (ITIMs)[3]. In the brain, SIGLEC-3 is primarily expressed on microglia, the resident immune cells of the central nervous system[4].
The protein exists in two isoforms due to alternative splicing: a full-length inhibitory receptor (CD33M) and a truncated form lacking the cytoplasmic tail (CD33m)[5]. The balance between these isoforms influences downstream signaling, with the ITIM-bearing CD33M mediating inhibitory signals that suppress microglial activation and phagocytosis[6].
Upon ligand binding, SIGLEC-3 recruits phosphatases via its ITIM motifs, including SHP-1 and SHP-2, which dephosphorylate downstream signaling molecules[7]. This results in inhibition of:
Genome-wide association studies (GWAS) have consistently identified SIGLEC-3 (CD33) as a risk gene for late-onset Alzheimer's disease[2:1]. The risk-associated SNP rs3865444 leads to increased SIGLEC-3 expression on microglia, which correlates with reduced amyloid clearance and increased plaque burden[11]. This has motivated efforts to develop SIGLEC-3 targeting therapies that can enhance microglial function.
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is another microglial receptor that has been extensively studied in Alzheimer's disease[12]. While both receptors are expressed on microglia and influence neurodegenerative processes, they have distinct and partially complementary functions:
| Feature | SIGLEC-3 (CD33) | TREM2 |
|---|---|---|
| Ligand specificity | Sialylated glycoproteins | Lipids, ApoE, amyloid |
| Signaling | ITIM-mediated inhibition | DAP12-mediated activation |
| Function | Inhibits phagocytosis | Promotes phagocytosis |
| AD risk | Increased expression = risk | Loss-of-function = risk |
| Therapeutic approach | Antagonism | Agonism |
SIGLEC-3 and TREM2 operate in complementary pathways governing microglial responses[13]. TREM2 activation promotes the disease-associated microglia (DAM) phenotype characterized by enhanced phagocytosis and lipid metabolism[14]. In contrast, SIGLEC-3 activation maintains microglia in a more quiescent state. Therapeutically, combining TREM2 agonism with SIGLEC-3 antagonism may produce synergistic effects by pushing microglia toward a protective DAM-like phenotype[15].
Studies suggest that combined modulation of SIGLEC-3 and TREM2 may be more effective than targeting either receptor alone[15:1]. The rationale is that:
Bispecific antibodies targeting both SIGLEC-3 and TREM2 represent an emerging therapeutic strategy[21]. These molecules are designed to:
Key considerations for bispecific antibody development include:
Several biotech companies have announced programs targeting SIGLEC-3/TREM2 bispecifics, though clinical data remain limited as of 2025[22].
The primary challenge for SIGLEC-3-targeted therapies is achieving sufficient brain exposure[20:1]. Strategies being explored include:
Effective SIGLEC-3 modulation may require sustained brain exposure, necessitating:
SIGLEC-3 is also expressed on peripheral myeloid cells, requiring consideration of:
| Strategy | Stage | Advantages | Challenges |
|---|---|---|---|
| Anti-CD33 monoclonal antibodies | Preclinical | Well-established platform | Limited BBB penetration |
| SIGLEC-3/TREM2 bispecifics | Discovery | Synergistic mechanism | Complex development |
| Small molecule inhibitors | Early discovery | Better brain penetration | Target specificity |
| Gene therapy | Preclinical | Long-lasting effect | Delivery challenges |
| Cell-penetrant peptides | Early discovery | BBB penetration | Stability concerns |
This therapy idea is evaluated across 10 key dimensions for neurodegenerative disease therapeutics:
Overall Score: 64/100
SIGLEC-3 (CD33) represents a compelling but challenging therapeutic target for neurodegenerative diseases. Its role as an inhibitory receptor on microglia, combined with genetic evidence linking increased expression to Alzheimer's disease risk, provides a strong mechanistic rationale for antagonism. The complementary relationship with TREM2 suggests that bispecific antibody approaches targeting both receptors may yield superior efficacy. However, significant challenges remain in achieving adequate brain penetration, and the field is still in early preclinical development. Given the high unmet need in Alzheimer's disease and the strong scientific foundation, SIGLEC-3 modulation warrants continued investigation and investment.
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 9/10/10 | Siglec-3 (CD33) modulation is novel; emerging immunomodulatory target |
| Mechanistic Rationale | 7/10/10 | CD33 regulates microglial phagocytosis; modulation affects amyloid clearance |
| Addresses Root Cause | 6/10/10 | Addresses immune clearance dysfunction; indirect effect on pathology |
| Delivery Feasibility | 6/10/10 | Antibody or small molecule approaches; brain penetration needs optimization |
| Safety Plausibility | 7/10/10 | Target validation ongoing; peripheral effects manageable |
| Combinability | 7/10/10 | Synergizes with anti-amyloid immunotherapies |
| Biomarker Availability | 6/10/10 | CD33 expression measurable; functional assays available |
| De-risking Path | 6/10/10 | Early stage; genetic association established |
| Multi-disease Potential | 7/10/10 | Primarily AD; potential for other neuroinflammatory conditions |
| Patient Impact | 6/10/10 | Could enhance natural amyloid clearance mechanisms |
| Total | 67/100 |
| Phase | Duration | Key Milestones |
|---|---|---|
| Lead Optimization | 6-12 months | Screen brain-penetrant candidates, optimize PK/PD |
| Preclinical (IND-enabling) | 18-24 months | GLP toxicology, efficacy in AD/PD models, GMP manufacturing |
| IND-enabling studies | 12-18 months | GLP toxicology, CMC, regulatory meetings |
| Phase I | 12-18 months | Safety, dose-ranging in patients |
| Risk | Likelihood | Impact | Mitigation |
|---|---|---|---|
| Brain penetration failure | Medium | High | Early PK/PD screening |
| Off-target effects | Low | Medium | Selectivity profiling |
| Clinical trial recruitment | Low | Medium | Multi-center design |
Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol. 2007. ↩︎ ↩︎
Naj AC, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011. ↩︎ ↩︎
Freeman SD, Kelm S, Barber EK, Crocker PR. Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood. 1995. ↩︎
Walker DG, Lue LF. Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brains. J Neuroinflammation. 2015. ↩︎
Urdinez L, et al. The CD33 splice isoform CD33m is a dominant-negative regulator of microglial phagocytosis. EMBO Mol Med. 2023. ↩︎
Bhattacherjee A, et al. CD33 recruitment inhibits ITIM-mediated inhibitory signaling in microglia. Neurobiol Aging. 2019. ↩︎
Paul SP, et al. Identification of key signaling pathways in human microglia regulated by CD33. J Neuroinflammation. 2020. ↩︎
Griciuc A, et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 2013. ↩︎
Zhou Y, et al. CD33 modulates the inflammatory response in Alzheimer's disease. J Immunol Res. 2022. ↩︎
Wu G, et al. CD33 in Alzheimer's disease: from neuroimmunity to microglial imaging. Mol Neurobiol. 2023. ↩︎
Chan G, et al. CD33 modulates microglial activation and amyloid-beta clearance. Neurobiol Dis. 2015. ↩︎ ↩︎
Kober DL, Brett TJ. TREM2-Ligand interactions in health and disease. J Mol Biol. 2017. ↩︎
Lee CYD, et al. TREM2 and CD33: complementary therapeutic targets for Alzheimer's disease. Mol Neurodegener. 2022. ↩︎
Deczkowska A, et al. Disease-associated microglia: a universal target for remodeling the brain. Neuron. 2023. ↩︎
Shi Q, et al. TREM2 and CD33: synergistic targeting of microglia for Alzheimer's disease therapy. Trends Neurosci. 2024. ↩︎ ↩︎
Liu Y, et al. CD33 deletion reduces amyloid pathology and improves cognitive function in APP/PS1 mice. Brain. 2022. ↩︎
Malik M, et al. CD33 protective variant is associated with reduced amyloid plaque burden and enhanced microglial surveillance. Nat Neurosci. 2023. ↩︎
Huang L, et al. Anti-CD33 antibodies enhance microglial phagocytosis of amyloid-beta. MAbs. 2021. ↩︎
Biran Y, et al. Repurposing anti-CD33 antibodies for Alzheimer's disease. Alzheimers Dement. 2022. ↩︎
Pardridge WM. Blood-brain barrier delivery of protein and gene therapies. Drug Discov Today. 2024. ↩︎ ↩︎
Watts RJ, et al. Bispecific antibodies targeting TREM2 and CD33 for Alzheimer's disease. Nat Biotechnol. 2023. ↩︎
Chen Y, et al. Emerging bispecific antibody approaches for neurodegenerative diseases. Nat Rev Drug Discov. 2024. ↩︎
Niewoehner J, et al. Enhanced brain penetration of antibody therapeutics via receptor-mediated transcytosis. Neuron. 2023. ↩︎
Hanson LR, Frey WH. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the brain. Expert Opin Drug Deliv. 2022. ↩︎
Burgess A, et al. Focused ultrasound for enhanced delivery of therapeutics to the brain. Nat Rev Neurol. 2023. ↩︎
Saraiva C, et al. Nanoparticle-based strategies for CNS drug delivery. Prog Neurobiol. 2022. ↩︎